United Kingdom

Zoetis Completes Purchase of Animal Health Assets of Abbott

Zoetis Inc. today announced that it has completed the purchase of the animal health assets of Abbott for a purchase price of $255 million, having fulfilled all closing requirements.

The purchase expands Zoetis’ companion animal product portfolio to bring veterinarians solutions for anaesthesia and treating pain and serious illnesses such as diabetes. It also brings novel cancer and pain compounds to the Zoetis pipeline for further development.

“We believe Zoetis’ scale, industry-leading field force, and global presence will rapidly expand the reach and penetration of these newly acquired, leading brands for the veterinary surgical suite,” said Zoetis Group President Kristin Peck, who oversees the company’s Strategy and Corporate Development organization. “The acquisition is a prime example of our value creation strategy to deploy capital to acquire products that enhance our portfolio and enable us to deliver more customized solutions to veterinarians.”

In conjunction with the completion of the transaction, Zoetis has commenced integration activities and disclosed the expected impact on its 2015 financial results.

  • Additional revenue of approximately $75 million for full year 2015
  • A negative impact of $0.03 cents per share on reported diluted EPS for full year 20151
  • A positive impact of $0.01 cent per share on adjusted diluted EPS for full year 20152

“Having completed the acquisition of these assets, we expect an accretive benefit to adjusted earnings in 2015 and expect a more significant benefit to be achieved in 2016 as we begin to more fully realize the synergies,” said Zoetis Executive Vice President and Chief Financial Officer Paul Herendeen. “We continue to focus on additional business development opportunities, internal investments, and prudent uses of our capital to create shareholder value.”

The company will provide further comments on the impact of the acquisition on its 2015 full year guidance when it announces fourth quarter and full year 2014 results on Feb. 11, 2015.


1Subject to final purchase price allocation.

2Adjusted net income and adjusted diluted earnings per share (non-GAAP financial measures) are defined as reported net income attributable to Zoetis and reported diluted earnings per share, excluding purchase accounting adjustments, acquisition-related costs and certain significant items.



Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to business plans or prospects, future operating or financial performance, expectations regarding products, future use of cash and dividend payments, and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013, including in the sections thereof captioned “Forward-Looking Information and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.


For Zoetis Media:
Elinore White, 1-973-443-2835
William Price, 1-973-443-2742

John O'Connor, 1-973-822-7088